Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Apr 28, 2026 - 30:21
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. On the latest BioCentury This Week podcast, BioCentury’s Lauren Martz a...
About This Episode
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA is an episode from BioCentury This Week by BioCentury. As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced...
Podcast
This episode belongs to BioCentury This Week.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Feb 17, 2026, 26:16 long, audio available.
Related Episodes
Continue listening to more episodes from BioCentury This Week.
Ep. 362 - AACR: Data and de-risking
Apr 23, 2026 - 25:06
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
Apr 21, 2026 - 44:02
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
Apr 14, 2026 - 33:38
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Apr 7, 2026 - 38:41
Ep. 358 - Europe's biotech challenge
Apr 2, 2026 - 23:32
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
Mar 30, 2026 - 28:38
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
Mar 24, 2026 - 33:59
Questions About This Episode
What is Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA about?
As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. On the latest BioCentury This Week podcast, BioCentury’s Lauren Martz assesses how the oral SERD landscape is evolving. Washington Editor Steve Usdin then discusses setbacks at FDA for an orphan therapy from Disc Medicine and a vaccine from Moderna, and why he is calling on life sciences industry leaders to publicly demand the dismissal of Vinay Prasad, FDA’s CSO, CMO, and director of CBER. View full story: 00:00 - Introduction 03:12 - Oral SERD Spotlight 11:40 - Setbacks at FDA 15:12 - Disc Medicine CRL To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text
Where can I listen to Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA?
You can listen to Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA from?
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA is an episode from BioCentury This Week by BioCentury.
How long is this episode?
This episode is 26:16 long.
When was this episode published?
This episode was published on Feb 17, 2026.
Can I save Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from BioCentury This Week?
Yes. This page shows related episodes from BioCentury This Week when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA?
You can listen to Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA is from BioCentury This Week by BioCentury.
What are the episode details?
Published Feb 17, 2026 and 26:16 long